Danaher Corporation $DHR Shares Acquired by Lee Danner & Bass Inc.

Key Points

• Lee Danner & Bass Inc. has increased its holdings in Danaher Corporation (NYSE:DHR) by 10.9%, acquiring an additional 1,602 shares to reach a total of 16,326 shares valued at approximately $3.225 million.
• Danaher Corporation recently reported an earnings per share (EPS) of $1.89, exceeding estimates, with revenue of $6.05 billion, indicating a year-over-year increase of 4.4%.
• The company announced a quarterly dividend of $0.32 per share, payable on October 31st, reflecting a 0.6% yield and a dividend payout ratio of 27.23%.

Lee Danner & Bass Inc. increased its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 10.9% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,326 shares of the conglomerate's stock after buying an additional 1,602 shares during the period. Lee Danner & Bass Inc.'s holdings in Danaher were worth $3,225,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in DHR. Nuveen LLC purchased a new stake in shares of Danaher in the 1st quarter worth about $833,941,000. Invesco Ltd. boosted its position in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after buying an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. boosted its position in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock worth $295,550,000 after buying an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP boosted its position in shares of Danaher by 33.2% in the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock worth $651,515,000 after buying an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC lifted its holdings in Danaher by 23.3% in the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock valued at $784,745,000 after purchasing an additional 722,636 shares in the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

Danaher stock opened at $222.75 on Friday. The stock has a market cap of $157.34 billion, a P/E ratio of 45.92, a price-to-earnings-growth ratio of 3.31 and a beta of 0.77. The company has a current ratio of 1.52, a quick ratio of 1.22 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average of $202.49 and a 200-day moving average of $198.02. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23.

Danaher (NYSE:DHR - Get Free Report) last released its earnings results on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, beating the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The company had revenue of $6.05 billion during the quarter, compared to analysts' expectations of $6 billion. During the same period in the prior year, the business posted $1.71 EPS. The business's revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio (DPR) is presently 27.23%.

Analyst Ratings Changes

DHR has been the topic of a number of recent research reports. Robert W. Baird set a $247.00 target price on shares of Danaher in a report on Wednesday. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Barclays upped their target price on shares of Danaher from $225.00 to $250.00 and gave the company an "overweight" rating in a report on Wednesday. Deutsche Bank Aktiengesellschaft upped their target price on shares of Danaher from $235.00 to $250.00 and gave the company a "buy" rating in a report on Wednesday. Finally, TD Cowen increased their price objective on shares of Danaher from $250.00 to $260.00 and gave the stock a "buy" rating in a report on Wednesday. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Danaher currently has an average rating of "Moderate Buy" and a consensus target price of $243.39.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the firm's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director directly owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 11.10% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.